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Abstract
Diabetic retinopathy (DR) is one of the most severe clinical manifestations of dia-
betes mellitus and a major cause of blindness. DR is principally a microvascular 
disease, although the pathogenesis also involves metabolic reactive intermediates 
which induce neuronal and glial activation resulting in disruption of the neurovas-
cular unit and regulation of the microvasculature. However, the impact of neural/
glial activation in DR remains controversial, notwithstanding our understanding as 
to when neural/glial activation occurs in the course of disease. The objective of this 
study was to determine a potential protective role of neuropeptide Y (NPY) using 
an established model of DR permissive to N-methyl-D-aspartate (NMDA)-induced 
excitotoxic apoptosis of retinal ganglion cells (RGC) and vascular endothelial growth 
factor (VEGF)-induced vascular leakage. In vitro evaluation using primary retinal en-
dothelial cells demonstrates that NPY promotes vascular integrity, demonstrated by 
maintained tight junction protein expression and reduced permeability in response 
to VEGF treatment. Furthermore, ex vivo assessment of retinal tissue explants shows 
that NPY can protect RGC from excitotoxic-induced apoptosis. In vivo clinical imag-
ing and ex vivo tissue analysis in the diabetic model permitted assessment of NPY 
treatment in relation to neural and endothelial changes. The neuroprotective effects 
of NPY were confirmed by attenuating NMDA-induced retinal neural apoptosis and 
able to maintain inner retinal vascular integrity. These findings could have important 
clinical implications and offer novel therapeutic approaches for the treatment in the 
early stages of DR.
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1  | INTRODUC TION
Diabetic retinopathy (DR) is the leading cause of visual loss in adults 
aged 20-74 years.1 The incidence of DR is expected to rise further 
due to the increasing prevalence of diabetes, ageing of the popula-
tion and increase in the life expectancy of individuals with diabetes.2 
Conventional clinical assessment and classification is based on clas-
sical microvascular features including the following: haemorrhage, 
lipid exudate, cotton wool spots and neovascularization, all observed 
predominantly in the inner retina.3 However, pre-clinical studies 
also demonstrate that components of the neurovascular unit, in-
cluding the inner and outer neurosensory retina, are disrupted in 
diabetes.4,5 Perturbed neuronal function reflected by impaired glu-
tamatergic and dopaminergic neurotransmitter signalling,6 altered 
dendritic fields7 and reduced synaptic protein expression has been 
documented.8 These changes ultimately leading to apoptosis of 
neurons alongside persistent uncontrolled diabetes.9 Additional di-
abetic changes include altered glial cell activation, demonstrated by 
impaired interconversion of glutamate and glutamine,10 regulation 
of potassium channels11 and subsequent expression of the gluta-
mate-aspartate transporter and intermediary filament proteins such 
as glial fibrillary acidic protein (GFAP). Diabetes also induces changes 
to retinal astrocytes, which located in the retinal nerve fibre layer 
and aligned with blood vessels provide contact with synapses,12 and 
where connexin expression is reduced in the early course of diabetes 
prior to astrocyte loss.13 Collectively, diabetes causes components 
of the retinal neurovascular unit to ‘dis-integrate’, and accordingly, 
DR should be recognized as a neurovascular degeneration and not 
solely a microvascular disease.14,15 Nevertheless, recognition that 
disruption of the neurovascular unit presents opportunities for new 
therapeutic strategies and/or molecular targets that may offer po-
tential for treating in the early stages of disease.
Neuropeptide Y (NPY) is one of the most abundant peptides in 
the mammalian central nervous system (CNS).16 NPY is a highly con-
served 36 amino acid peptide which binds to a family of G protein–
coupled receptors Y1-6,17 expressed in the retina of several species 
including mice.18-21 Studies demonstrate putative neuroprotective 
effects of NPY in different CNS regions,22 including inhibition of 
glutamate release in rat hippocampus and striatum.23 Selective ac-
tivation of NPY receptors has also been shown to protect mouse 
hippocampal cells from excitotoxic lesions.24 Specific activation 
of Y2 receptor is effective in a transient middle cerebral artery 
occlusion model of ischaemia,25 and NPY receptor signalling sup-
presses glutamate-induced necrosis and apoptosis in retinal neural 
cells,26 modulates retinal ganglion cell (RGC) physiology and elicits 
neuroprotective effects in vitro.27 Although no direct evidence in 
retinal endothelium, NPY can induce migration and proliferation 
of endothelial cells via its receptors and regulate their function.28 
Conversely, a recent study demonstrates that NPY treatment in a 
model of acute retinal ischaemia reduced retinal function and tissue 
damage.29
In light of the reported decrease in mRNA and protein levels for 
NPY in diabetic retina,30 as well as observations of NPY function, we 
examined whether administration of NPY would extend and offer 
protection of the neurovascular multicellular complex in the diabetic 
retina. Using in vitro platforms, we first assessed whether neuropro-
tective actions of NPY could reduce the sensitivity of retinal neu-
rons to glutamate-induced excitotoxicity. Additionally, we evaluated 
the potential intracellular signalling pathways of NPY suppression of 
vascular endothelial growth factor (VEGF)-induced vascular perme-
ability in retinal endothelial cells. Finally, we established an in vivo 
model of DR, permissive to accelerated glutamate excitotoxicity and 
VEGF-induced vascular leakage to evaluate whether NPY is neuro-
protective, attenuating retinal neural apoptosis and able to maintain 
inner retinal vascular integrity.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and viability
Primary Retinal Microvascular Endothelial cells from mouse 
(MRMECs) or human (HRMECs) were purchased from company 
(Generon) and were cultured in Complete Mouse and Human 
Endothelial Cell Medium, respectively (Generon). We used the MTT 
assay to assess cell viability.
2.2 | In vitro vascular permeability assay
Permeability visualization experiments were performed on 
18 × 18 mm glass coverslips as previously described.31 For assays, 
serum-free culture medium supplemented with the treatment (com-
binations of NPY, N-methyl-D-aspartate [NMDA], VEGF) was added 
for a further 24 hours. Then, fluorescein-streptavidin was directly 
added to the culture medium for 5 minutes and washed twice with 
PBS before cell fixation with 3.7% paraformaldehyde (PFA) in room 
temperature (RT) subjected to immunofluorescence staining accord-
ing to the manufacturer's instructions.
2.3 | SDS-PAGE analysis
For analysis of protein levels, cultured MRMECs cells were rinsed 
twice with ice-cold PBS before lysis with ice-cold CelLytic™ MT 
Cell Lysis Reagent (Sigma-Aldrich). Cell lysates were centrifuged 
at 14 000 g for 10 minute at 4°C, the supernatant was transferred 
to fresh tubes, and Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific) was used to determine the protein concentration in 
each sample. Then, the equal protein was mixed with 4× SDS sam-
ple buffer, boiled for 10 minutes at 90°C and resolved using 4% 
to 20% NuPAGE gels (Invitrogen). Proteins were transferred to 
PVDF membranes (Invitrogen), blocked with 5% skimmed milk for 
2 hours, rinsed and incubated overnight at 4°C with the follow-
ing primary antibodies: anti-ZO-1 (ab2272, Merck, UK; 1:1000), 
anti-p38 MAPK (#8690, Cell Signaling Technology; 1:1000), 
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anti-p44/42 MAPK (#4695, Cell Signaling Technology; 1:1000) 
and β-actin (Cell Signaling Technology; 1:1000). Excess antibody 
was then removed by washing the membrane in PBS/ 0.1% Tween 
20, and the membranes were incubated for 2 hours with horse-
radish peroxidase-conjugated secondary antibodies (Abcam, UK; 
1:2000). Following further washes in PBS/0.1% Tween 20, protein 
signals were developed with ECL reagent (Sigma) and captured by 
an electronic imaging system (Konica Minolta). Restore™ PLUS 
Western Blot Stripping Buffer (Thermo Fisher Scientific) was used 
to re-blot the membranes. The density of protein was quantified 
using the ImageJ.
2.4 | Retinal explant culture ex vivo model
Retinal explant culture was performed as previously described.31,32 
Healthy Han Wistar rat's retina (20-old-day) was dissected into four 
equal-sized pieces, and the explants were separately transferred 
onto 12-mm-diameter filters (0.4 μm pore, Millipore) with the RGC 
side facing up. The filters were placed into the wells of a 24-well 
plate, and each contained 800 μL of culture media. Retinal explant 
cultures were maintained in humidified incubators at 37°C and 5% 
CO2. Half of the media was refreshed on day 1 and every second day 
thereafter.
2.5 | Immunofluorescence staining
Eyes from 6-month diabetic mice and cultured rat retinal explants 
were fixed with 4% PFA and snap-frozen in OCT (VWR Chemicals). 
For immunostaining, 8-μm cryosections were washed in PBS and 
blocked in 5% normal goat serum (NGS), 2% BSA and 0.3% Triton 
X-100 in PBS for 30 minutes at RT followed by incubating with 
the following primary antibodies: mouse anti-GFAP (#3670, Cell 
Signaling Technology, 1:200), mouse anti-Brn-3a (sc-8429, Santa 
Cruz Biotechnology, Inc, 1:50) and rabbit anti-Rhodopsin (ab3424, 
Abcam, 1:100)31 overnight at 4°C. The secondary antibodies Cy3 
conjugated goat antimouse IgG (Merck) and Alexa Fluor 488-la-
belled donkey anti-rabbit IgG (Invitrogen), both with 1:200 dilu-
tion in 2% BSA in PBS at RT for 1 hour in the dark. DAPI (Vector 
Laboratories) was used to show nuclei in sections. Retinal explants 
were mounted in antifading medium. Images were captured by 
Leica SP5-AOBS confocal laser microscope and processed with 
ImageJ.
For retinal flatmount, the whole retina was permeabilized with 
0.2% Triton X-100 and blocked in PBS with 5% NGS for 2 hours RT. 
The retinas were then incubated with the primary antibodies (an-
ti-Brn-3a [1:50] and anti-GFAP [1:200]) for 48 hours at 4°C. Tissues 
were washed before incubation with secondary Alexa Fluor 549-la-
belled donkey antimouse IgG (1:200, Invitrogen) for 2 hours at RT, 
then washed in PBS, flat mounted onto microscope slides and cov-
ered with antifading mounting medium (with DAPI) for confocal 
microscopy.
2.6 | Quantitative real-time RT-PCR
Total RNA extraction was carried out using TRIzol™ Reagent (Life 
Technologies, UK) according to the manufacturer's instructions. 
Total RNA was quantified by NanoDrop, and cDNA was syn-
thesized using the ImProm-IITM Reverse Transcription System 
(Promega). Then, cDNA was amplified using the Power SYBR® 
Green PCR Master Mix Reagent (Life Technologies). Primer se-
quences used were as follows: β-Actin, forward 5′-gggaaatcgt-
gcgtgacattaag, reverse 5′-tgtgttggcgtacaggtctttg; NPY, forward 
5′-actccgctctgcgacactacat, reverse 5′-gcgttttctgtgctttccttca; 
VEGF, forward 5′-ttactgctgtacctccacc, reverse 5′-acaggacggctt-
gaagatg; Angiopoietin-like 4 protein (ANGPTL-4) and forward 
5′-ttggtacctgtagccattcc, reverse 5′-gaggctaagaggctgctgta. The 
equation fold change = 2−ΔΔct was used for calculation relative 
changes in expression levels.
2.7 | TUNEL assay
The terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) assay was performed according to the manufacturer's in-
structions (Roche). In brief, retinal explants were fixed with 4% PFA 
and washed in PBS, and retinas were permeabilized with 0.1% Triton 
X-100 for 1 hour and rinsed three times with PBS, before incubation 
with the TUNEL reaction mixture for 1 hour at 37°C. Retinal explants 
were mounted using antifading mounting medium, and apoptotic cells 
were observed using Leica SP5-AOBS confocal laser microscope.
2.8 | Type 1 diabetic mouse model
All procedures were conducted under the regulation of the United 
Kingdom Home Office Animals (Scientific Procedures) Act 1986 and 
were in compliance with the Association for Research in Vision and 
Ophthalmology statement for the use of animals in ophthalmic and 
vision research.
Adult (6-8 weeks) C57BL/6J male mice were obtained from 
Charles River Laboratories. Type I diabetes was induced by five con-
secutive days intraperitoneal injections with streptozotocin (STZ) 
(Sigma-Aldrich; 40 μg/g bodyweight in 0.1 mol L−1 citrate buffer).33 
Control mice were injected with citrate buffer alone. Diabetes was 
confirmed by measuring urine glucose (14 days after the onset of 
diabetic induction, >300 mg/dL considered diabetic; overall disease 
incidence 88%).
2.9 | Intravitreal administration of NPY, 
VEGF and NMDA
In vivo retinal vascular permeability was assessed as previously de-
scribed.34 Briefly, the pupils of 3-month-old diabetic mice were di-
lated using topical 1% tropicamide before induction of anaesthesia. 
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Mice received the following intravitreal injections (2 µL) with a 33-
gauge needle into one eye: VEGF (100 ng); NPY (10 nmol); VEGF with 
NPY combined; and PBS vehicle. Forty-eight hours after the first in-
jection, mice received tail vein injections of Evans blue (200 µL, 2%). 
Mice were killed 10 minutes later, and eyes were fixed with 4% PFA 
for 2 hours. Retinal flatmounts were mounted in antifading medium, 
and images were captured by Leica SP5-AOBS confocal laser micro-
scope and processed with ImageJ.
NMDA (Sigma-Aldrich) was used to induce excitotoxicity of RGC 
in the retina,31 under experimental conditions described above. A 
dose-response was undertaken previously to ascertain the optimal 
dosing of NPY (5 to 20 nmol); then, mice received the following 
intravitreal injections (2 µL) with a 33-gauge needle into one eye: 
NMDA (10 nmol); NPY (10 nmol); NMDA with NPY together; and 
PBS vehicle. Mice were killed in 2 days following NMDA injection, 
and eyes and optic nerves were isolated. Eyes were fixed in 2% PFA 
for 2 hours for immunofluorescence staining.
2.10 | Electroretinography (ERG) and optical 
coherence tomography (OCT) measurements
In vivo imaging was performed in anaesthetized mice using the Micron 
IV retinal imaging system (Phoenix Research Laboratories). Pupils were 
dilated with tropicamide (1%) eye drops and positioned on a regulated 
temperature pad at 37°C to maintain constant body temperature. 
Subdermal needle electrodes were inserted underneath the skin at the 
base of the tail (ground electrode) and between the eyes on the fore-
head (reference electrode). Corneas were lubricated with coupling gel, 
the objective/electrode was advanced near the corneal surface, and 
deep red illumination was used to focus on the retina. Responses to 
focal light stimuli (1mm diameter; spot size D) were recorded at lumi-
nance ranging from −0.9 to 3.9 log cd*sec/m2. Data are displayed as the 
mean amplitude (in µV) of the a-wave (as a measure of photoreceptor 
function) and b-wave (as a measure of bipolar cell function).
2.11 | Statistics
Results are therefore presented as means ± standard deviation (SD). 
Differences between groups were analysed by Student's t test or 
analysis of variance (ANOVA). All the analysis was performed using 
GraphPad Prism 6 (GraphPad Software, version 6.01). The signifi-
cant differences were considered at P ≤ .05.
3  | RESULTS
3.1 | Diabetes drives neurovascular dysfunction, 
including Müller cell activation and ganglion cells loss
To understand how diabetes influences the neurovascular unit in the 
eye, we first confirmed what alterations to vasculature and neural 
retina occur in STZ-induced diabetic model. In vivo monitoring of 
STZ injected mice and controls permitted longitudinal assessment of 
retinal function by ERG. There was a steady decline of ERG function 
in diabetic eyes from 6 to 25 weeks, and by 6 months a significant 
suppression of the b-wave, indicative of dysfunctional Müller and 
bipolar cells (Figure 1A,B). Ex vivo assessment of vascular integrity 
using retinal flatmount demonstrates leakage of Evans blue dye is 
significantly increased in the diabetic retina (219.6 ± 29.2%) com-
pared to control retina (100.0 ± 9.4%, P ≤ .001; Figure 1C,D). The 
number of Brn3a + cells, a specific marker of RGC, was quantified 
on tissue sections and was significantly decreased by 43.6 ± 12.8% 
of normal controls (Figure 1E,F). In the healthy retina, Müller cells do 
not express high levels of GFAP, a common marker of reactive glio-
sis35; however, in the diabetic retina an increase MFI of 76.7 ± 17.1% 
of GFAP expression was observed (Figure 1G,H). Next, we assessed 
whole retinal tissues for altered expression of gene transcripts en-
coding NPY and vasoproliferative factors, VEGF and ANGPTL-4. 
In 6-month diabetic retinas, there was significantly reduced NPY 
mRNA levels detected (Figure 1I), with corresponding increased ex-
pression of the pro-angiogenic VEGF and ANGPTL-4 (Figure 1J).
3.2 | NPY regulates the tight junctions of retinal 
endothelium through MAP kinase
The observed reduction in NPY gene expression in the diabetic 
retina correlates with an increase in vascular permeability and pro-
angiogenic factors. We therefore wished to interrogate the potential 
role of NPY in maintenance and regulation of the retinal vascular 
barrier. Using an in vitro approach, we examined the effects of NPY 
in terms of maintaining the tight junctions in cultured MRMECs. 
First, we established the response profile of MRMECs follow-
ing incubation for 24 hours with a range of VEGF and NPY doses 
(Figure 2A,B). VEGF had no effect on cell viability, and NPY was toxic 
only at the high dose of 40 µmol L−1. SDS-PAGE analysis of MRMEC 
cell lysates demonstrated that VEGF induced a dose-dependent re-
duction of ZO-1, whereas NPY increased significantly ZO-1 expres-
sion (Figure 2C,D). For subsequent in vitro assessment, the following 
doses were used: VEGF 100 ng/mL and NPY 10 µmol L−1. At these 
concentrations, MRMEC expression of ZO-1 following incubation 
with VEGF resulted in a significant (43%) reduction, whereas NPY 
increased expression by 40% compared to untreated controls. When 
cells were pre-treated with NPY, applied 6 hours before VEGF, there 
was a significant increase in ZO-1 expression (33% higher than VEGF 
alone) equivalent to expression of the control cells (Figure 2E). To 
understand the potential mechanism for the protective effect of 
NPY, we next examined expression of mitogen-activated protein 
kinase (MAPK), involving in regulating the expression of tight junc-
tion proteins.36 Our results indicate that treatment of MRMECs with 
NPY increased the expression of ZO-1 and down-regulated MAPK 
isoforms p38-MAPK and p44/p42 MAPK (P ≤ .05; Figure 2F,G). NPY 
was able to reverse the loss of ZO-1 and increased permeability in-
duced via VEGF.
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To demonstrate how NPY-mediated increase in expression of ZO-1 
influenced the barrier function in MRMECs, we next performed an in 
vitro vascular permeability assay. This approach permits dual assess-
ment of tight junction expression and extent of monolayer leakage 
in response to NPY and VEGF treatment. When treating MRMEC 
cell monolayers with VEGF (100 ng/mL, 24 hours), a 7-fold increase 
in fluorescent area (fluorescent-positive intercellular signal) com-
pared to control (untreated cells) was observed, indicating increased 
vascular permeability. NPY attenuated vascular permeability through 
preservation of the integrity of cellular tight junction as demonstrated 
by a 30% reduction of fluorescent area compared to VEGF alone 
(P < .05) (Figure 2H,I). In addition, ZO-1 immunostaining confirmed the 
F I G U R E  1   Diabetic retinas exhibit neurovascular dysfunction. Representative images captured from retinal flatmounts and sections 
obtained from age-matched wild-type and 6-month-old DM. A, B, ERG recorded a-wave and b-wave in scotopic conditions show 
photoreceptor and inner retina electroretinogram data, respectively. C, Fluorescent images of retina demonstrated differences in vascular 
integrity (leakage of Evans blue dye, which appears as red). Scale bar = 100 μm. D, The mean fluorescence intensity of Evans blue was 
quantified using ImageJ and shown to be significantly increased in the DM group. E, Immunostaining of tissue sections retinal ganglion cell 
marker Brn-3a (red) counterstained with DAPI (blue). Scale bar, 100 μm. F, Quantification of Brn-3a+ expression as percentage of control. G, 
Immunostaining of retinal sections with retinal macroglial cell marker GFAP (red) counterstained with DAPI (blue). Arrows indicate activated 
Müller cells in diabetic mice. Scale bar, 100 μm. H, The mean fluorescence intensity of GFAP staining was quantified using ImageJ and shown 
to be significantly increased in the DM group. Retinal ganglion cell layer (GCL), inner nuclear layer (INL) and outer nuclear layer (ONL). I, J, 
Gene expression in control and diabetic retina demonstrates significant reduction in NPY and increase in pro-angiogenic factors (VEGF and 
ANGPTL-4). Data represent means ± SD of relative values vs control from three independent experiments. *P < .05; **P < .01; ***P < .001; 
****P < .0001, statistical analysis was performed with unpaired student's t test
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F I G U R E  2   NPY regulates the tight junctions of retinal endothelium through MAP kinase. A, B, MRMEC cell monolayers were serum 
starved for 24 h, before incubation with complete medium supplemented with NPY or VEGF for a further 24 h. Cell viability was determined 
in each group using the MTT assay. Data were normalized by control. C, D, SDS-PAGE analysis demonstrating altered ZO-1 expression 
in MRMEC cell lysates treated with NPY (0-20 μmol L−1) or VEGF (0-200 ng/mL). E, ZO-1 expression in MRMECs stimulated with NPY 
(10 μmol L−1), VEGF (100 ng/mL) or NPY + VEGF (pre-incubated with NPY for 6 h before addition of VEGF). F, G, ZO-1, p44/p42 MAPK 
and p38 MAPK protein expression in MRMECs treated with NPY (10 μmol L−1). H, Immunostaining of MRMECs for fluorescein-streptavidin 
to detect permeable areas and for ZO-1 to show cell-cell contact; cells deprived of serum for 24 h and incubated in the presence of NPY 
(10 μmol L−1), VEGF (100 ng/mL) or NPY + VEGF (pre-incubated with NPY for 6 h before addition of VEGF) for 24 h (n = 4 per group). I, 
Fluorescein intensity associated with DAPI expression was calculated by ImageJ in all treatment groups. Scale bar, 50 µm. Data represent 
means ± SD of relative values vs control from three independent experiments. *P < .05; **P < .01; ***P < .001; statistical analysis was 
performed with one-way ANOVA with Dunn's test for multiple comparisons
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breakdown integrity of tight junction following VEGF treatment, which 
was similarly partially prevented by NPY pre-treatment (Figure 2H). 
To assess whether NPY modulation of murine endothelial cells could 
be extended to human and thus bring a translational understanding 
of the role of NPY, experiments were also performed using HMRECs, 
demonstrated similar protective effects and maintained ZO-1 expres-
sion (Figure S1A). To model microvascular disturbance observed in 
the hyperglycaemic retina,37 we determined the angiogenic potential 
of HRMECs in response to NPY under high glucose (HG) conditions. 
Utilizing the in vitro tube formation assay, quantitative analysis showed 
that HRMEC tube length was significantly reduced with HG exposure 
(50 mmol L−1) compared with control group (5.5 mmol L−1 glucose), 
whilst NPY co-treatment under HG conditions maintained the angio-
genic capacity (P < .05; Figure 1B,C).
3.3 | NPY inhibits VEGF-induced vascular 
permeability in diabetic mice
The in vitro data demonstrate that NPY can modulate VEGF-induced 
vascular changes, so we next investigated whether this protective 
effect on vascular integrity translated to an in vivo setting. Groups 
of 6-month-aged diabetic mice were treated with a single intravitreal 
injection of VEGF (100 ng), NPY (10 nmol) or NPY + VEGF and clini-
cally assessed at 48 hours post-injection. Clinical OCT assessment 
demonstrated that VEGF or the combined VEGF + NPY treatments 
did not alter structural integrity as measured by retinal thickness 
(Figure 3A,B).
Vascular leakage was then assessed by extravasation of intra-
vascular Evans blue dye (EB) in the different treatments. Retinal 
flatmounts exhibited that intravitreal injection of VEGF results in 
a 4.8-fold increase in extravasation of Evans blue as confirmed via 
mean fluorescent intensity compared to control. Intravitreal injec-
tion of NPY together with VEGF decreased the leakage in retinal 
vessels by 36% compared to VEGF alone (Figure 3C,D). On the con-
trary, minimal vascular permeability of EB was observed in retinas 
receiving vehicle (PBS control) or NPY alone injections (P < .01).
3.4 | NPY protects retinal ganglion cells against 
apoptotic cell death induced by NMDA ex vivo and 
in vivo
As NPY receptors are expressed in the inner retina and recognition 
that RGC are perturbed in diabetes,38 we then wished to evaluate 
whether NPY played a homeostatic role and exerted a protective 
effect to preserve RGC. To investigate this further, the NMDA-
induced RGC excitotoxic model was employed in retinal explants.31
TUNEL + cells were quantified indicate NMDA treatment leads 
to a 4.8-fold increase in apoptotic cell number. Treating explants 
for 6 hours with NPY (10 µmol L−1) prior to exposure to NMDA de-
creased the cytotoxic effects, as presented by a significant reduc-
tion in TUNEL + cells by 38% as compared to NMDA alone (P < .05; 
Figure 4A, B). NPY treatment alone results in comparable low 
TUNEL + cells in comparison with control retinal explants.
To further elucidate with an in vivo correlate, we analysed flat-
mounts of diabetic eyes exposed to NMDA for 24 hours as a model 
of induced neuronal excitotoxic damage. A dose-response was 
tested prior to confirm the optimal dosing of NPY (5 to 20 nmol), 
which showed that a 10 nmol NPY dose provided the optimal pro-
tective effect in perturbing NMDA-induced RGC apoptosis model 
(Figure S2A,B). In diabetic eyes, administration of NMDA alone re-
duced the overall total retinal thickness by 23% compared to disease 
controls. However, the combined administration of NPY and NMDA 
the extent of cell loss is significantly reduced by 16% compared to 
NMDA alone (P < .05; Figure 4C,D). Similarly, ERG responses demon-
strate that eyes receiving a combined NPY and NMDA injection have 
improved functional responses, with increased a-wave and b-wave, 
compared to NMDA alone, although these were not statistically 
significant in b-wave (Figure 4E,F). Retinal wholemount assessment 
from diabetic eyes receiving NMDA shows a 7.9-fold increase in 
TUNEL + cells compared to control. The combined NPY injection 
leads to a significant reduction in TUNEL + cells (from 7.9-fold to 4.1-
fold of control; P < .05; Figure 4G,H).
3.5 | NPY restored neurovascular function in 
diabetic retinas in vivo
To determine whether the positive effects of NPY extended to offer 
long-term protection in the diabetic retina, NPY was administered via 
intravitreal injection at 3 and 5 months post-induction of diabetes. 
Clinical assessment by OCT to measure retinal thickness and ERG to 
determine changes in retinal function was performed at regular inter-
vals throughout the experimental time course. Representative clinical 
assessment at 4 months (Figure S3) showed no significant changes to 
the fundal appearance, total retinal thickness or ERG response be-
tween NPY-injected eyes and age-matched control eyes. Whilst the 
total retinal thickness was slightly reduced in the diabetic eyes, this 
was not significant. At 6 months following induction of diabetes, there 
was no difference in retinal thickness in the NPY-injected eyes com-
pared to age-matched control eyes. However, the inner plexiform layer 
thickness in DM groups was reduced by 42% compared to control 
group and the inner plexiform layer thickness in the NPY treated group 
was increased by 47% compared to DM group. Cell loss occurred pre-
dominantly in the inner plexiform layer (IPL; Figure 5A-C). ERG assess-
ment also demonstrates that NPY administration increased a-wave 
and b-wave amplitudes to levels equivalent to age-matched non-dia-
betic controls (P < .05; Figure 5D). These data support a notion that 
diabetic eyes injected with NPY had sustained neuronal cell function. 
To confirm whether the protective effect of NPY was evident in gan-
glion cells and astrocytes, retinal flatmounts were prepared for ex vivo 
immunohistochemistry assessment. Quantification of Brn-3a + RGC 
numbers in the diabetic retina shows a 66% reduction in cell numbers 
compared to age-matched controls. By contrast, DM eyes treated with 
NPY demonstrate a significant increase in Brn-3a + cells (from 34% to 
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59% of control) (P < .05; Figure 5E,F). Retinal glial coverage was evalu-
ated by staining with GFAP, showing widespread loss of glial coverage 
was observed in diabetic retina (Figure 5G). The relative glial coverage 
in the diabetic retina was significantly reduced by 55% compared to 
control retina. The diabetic eyes treated with NPY demonstrated a sig-
nificant increase by 49% in glial cell coverage compared to untreated 
diabetic eyes (P < .05; Figure 5H). Vascular integrity assessment by ex-
travasation of EB dye showed a 3-fold increase in the diabetic retina 
as compared to control eyes, and this was remarkably reduced in the 
NPY-treated group (P < .05; Figure 5I,J).
4  | DISCUSSION
In this study, we demonstrate a protective role of NPY in the retina, 
preventing loss of RGC and vascular leakage in diabetic mice in vivo. 
These findings are supported by in vitro and ex vivo evidence of 
NPY-mediated protection of MRMECs and RGC. The data support 
how modulation of neurovascular unit may offer therapeutic oppor-
tunities to prevent progression of DR.
The pathogenesis of DR is highly complex and a multifactorial 
process. Hyperglycaemia perturbs the metabolic and haemodynamic 
equilibrium, altering the molecular signature of multiple different 
cell types, principally endothelial cells and pericytes in the retina. 
Diabetes elicits the formation of advanced glycation end products 
and reactive intermediates of altered metabolism, increased oxida-
tive stress, which ultimately drives progressive neural and vascular 
damage.39-41 There are also reported data suggesting that DR results 
from changes to the neurovascular unit rather than isolated neurog-
lial or vascular alterations.42,43 The in vivo clinical assessment detail-
ing the changes in ERG response and OCT retinal thickness in the 
DM mice supports previous reports which demonstrate a progres-
sive neuronal injury at 6 weeks after induction of diabetes.44 Whilst 
the ERG technology available permitted reproducible and reliable 
recording of a-wave and b-wave, to fully evidence the contribution 
of RGCs precise measurements of photopic negative responses are 
required. As ERG reflects the overall function of the retina (depen-
dent on intact and functioning RGC), we assessed Brn-3a expres-
sion and the change in RGC number as an indirect surrogate of 
function. Furthermore, in addition to vascular disruption we have 
shown there is significant neuronal impairment (reduced numbers 
of Brn-3a + RGC and activation of GFAP + retinal glial) at 6 months, 
which supports that dysfunction of retinal neurons occurs early fol-
lowing the onset of diabetes. Considering the current data together 
with previous reports, there is compelling evidence to support that 
DR is a consequence of neurovascular unit disruption. Reduction of 
NPY expression (as we demonstrate in DM mice) may be associated 
with increased retinal neuron apoptosis and development of DR. 
F I G U R E  3   NPY inhibits VEGF-induced vascular permeability in diabetic mice. Groups of 3-month-old diabetic mice received intravitreal 
injections of NPY (10 nmol), VEGF (10 nmol) or NPY in combination with VEGF (n = 6 per group). A, B, At 24 h post-injection, clinical OCT 
images were acquired, and retinal thickness quantified. Data are representative of two measurements per retina. C, Representative ex vivo 
retinal flatmount images prepared 48 h following treatment demonstrate differences in the vasculature (leakage of Evans blue dye, which 
appears as red). Scale bar = 1 mm. D, The fluorescent intensity of Evans blue was quantified by ImageJ. **P < .01; ****P < .0001, statistical 
analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons
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This would suggest that normal levels of NPY are critical to the ho-
meostasis and maintenance of neurovascular unit.
Increased vascular permeability in diabetes is recognized as a 
complex process involving multiple signalling pathways, mediated 
principally by VEGF which disrupts the integrity of endothelial cell-
cell junctions.45 Among the various protein components of tight 
junctions, ZO-1 is a phosphoprotein that participates in multiple 
protein-protein interactions regulating tight junction integrity.46 
VEGF disrupts tight junctions by altering phosphorylation of ZO-1 
and occluding through a Src-dependent pathway.47 In our experi-
ments, and in accordance with previous work,48 we demonstrate 
the disruptive effects of VEGF on the expression of tight junction 
protein ZO-1 in endothelial cells. Moreover, we demonstrate that 
VEGF and NPY have opposite effects modulating the expression 
of ZO-1 in vitro using the MRMEC cell monolayers. Treatment 
with NPY increased expression of ZO-1, accompanied by reduc-
tion of the phosphorylated MAPK isoforms, supporting our initial 
hypothesis that NPY maintains vascular integrity, and this is de-
pendent on MAPK inhibition. The PKC-MAPK-NF-κB pathway is 
recognized to modulate the expression of tight junction proteins 
and the barrier function in various organs or cells.49 Targeted in-
hibition of protein kinase C zeta (PKCζ) reduces NF-κB activation 
and protects expression tight junction complex and cell permeabil-
ity in retinal endothelial cells.50 In addition, NPY has been shown 
to inhibit nuclear translocation of NF-κB in microglia challenged 
with IL-1β, thus preventing IL-1β-induced nitric oxide release and a 
further mechanism to protect and regulate the endothelial barrier 
function.51,52
Our previous studies using in vitro vascular permeability assay 
clearly demonstrate VEGF mediated increase in retinal endothelial 
F I G U R E  4   NPY protects retinal ganglion cells against apoptotic cell death induced by NMDA. A, B, Representative images showing 
TUNEL + cells in rat retinal explants exposed to NMDA (10 µmol L−1), NPY (10 µmol L−1) or pre-treated with NPY 6 h before NMDA exposure, 
showing TUNEL+ (red) and cell nuclei stained with DAPI (blue). Scale bar, 50 µm. Quantification of TUNEL + cells expressed as percentage 
of control. Groups of 3-month-old diabetic mice received intravitreal injections of NPY (10 nmol), NMDA (10 nmol) and NPY in combination 
with NMDA (n = 6 per group). C, D, At 48 h post-injection, OCT images show intravitreal NMDA results in reduced retinal thickness and 
NPY partially protects. ONH = optic nerve head. Data are representative of two measurements per retina. E, F, ERG a-wave and b-wave 
responses represented by mean values of amplitudes in scotopic conditions. G, H, Representative images of retinal whole mounts prepared 
for TUNEL staining and ImageJ analysis of confocal images. *P < .05; **P < .01; ***P < .001; ****P < .0001, statistical analysis was performed 
with one-way ANOVA with Dunn's test for multiple comparison, and EGF was analysed using two-way ANOVA for multiple comparison
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cell monolayer permeability,31 and when the assay was deployed 
here, results show that NPY suppressed VEGF-induced monolayer 
leakage and permeability. In addition, NPY treatment enhances 
stability of ZO-1 proteins at cell-cell contacts in human retinal 
endothelial monolayer, coincident with leakage of fluorescence. Our 
data suggest the protective effect of NPY on the integrity of the reti-
nal endothelial barrier is likely due to its ability to induce stabilization 
of tight junction complexes. Furthermore, and relevant to DR, our 
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observations from the diabetic mice demonstrate the protective role 
of NPY against VEGF-induced microvascular permeability in vivo. 
The protective effects of NPY are similar to another neuropeptide, 
substance P,53 which we previously demonstrated can maintain and 
support retinal vascular integrity.
Other alterations of diabetic retina include the increased frequency 
of apoptosis of retinal cells. Barber and co-workers38 previously doc-
umented increased apoptosis of retinal ganglion cells (RGC) in exper-
imental diabetes in rats and diabetes mellitus in humans. Similarly, we 
report that in the retinas of STZ-induced DM, there is a significant de-
crease of retinal thickness in DM compared with controls. Interestingly, 
segmentation analysis of retinal OCT images indicates cell loss occurs 
primarily in the retinal inner plexiform layer (IPL), a layer comprising 
a dense reticulum of fibrils predominantly formed by interlaced den-
drites of RGC. There is evidence that ganglion cell death in DR occurs 
via glutamate-mediated toxicity.54 Glutamate is the major excitatory 
neurotransmitter in the retina and is involved in neurotransmission 
from photoreceptors to bipolar cells and from bipolar cells to ganglion 
cells. Elevated levels of glutamate are implicated in neurodegeneration 
and its toxic effects on the retina, particularly in RGC are well-estab-
lished.55,56 In both human diabetes and experimental models of dia-
betes, glutamate levels are shown to be elevated.54,57,58 Expression of 
NPY in the mouse retina affords neuroprotective effects,26 confirmed 
by in vitro observations that rat retinal cells are protected from NMDA-
induced toxicity,59 although the NPY receptor subtype(s) involved in 
this neuroprotective effect remain unknown. In the current study, we 
extend understanding of the beneficial effects and show that NPY ex-
erts neuroprotective properties on RGC in NMDA-induced neuro-ex-
citotoxicity apoptotic cell death both in ex vivo retinal explants and in 
the diabetic animal model. Whilst arguably switching of species may 
confound, we selected to use the rat retinal explant model as an es-
tablished, more easily manipulated and robust assay for RGC assess-
ment.31,60,61 Although the RGC subtypes vary between species, the 
anatomical location and number are largely equivalent.
In terms of the intracellular mechanisms underlying the NPY neu-
roprotective role against cell death induced by glutamate, the protec-
tive effects of NPY are thought to be linked to inhibition of glutamate 
release, as reported in the CNS, specifically the hippocampus.23,25 In 
rat retinal cultures, NPY inhibits both the [Ca2+] increase induced by 
KCl62 and the aspartate release in these cultures (unpublished observa-
tions).26 Different intracellular signalling pathways are reported to fa-
cilitate NPY-mediated neuroprotection and the involvement of ERK1/2 
and Akt pathways in Parkinson's disease model,63 as well as PKA and 
p38K in retinal neural cells.26 In terms of neuroprotection, we speculate 
that NPY similarly exerts a protective effect through MAPK signalling, 
as MAPK has been shown to regulate tight junction function. Future 
work in our laboratory will explore those questions.
In contrast, recent publications suggest NPY does not exert a 
protective effect in the retina29 and that NPY shows no association 
at gene level (SNP in NPY2R gene) in patients with diabetes.64 These 
reports utilize notably different models, addressing different questions 
but taken together, may suggest that NPY signalling is context-depen-
dent, with the potential to exert both beneficial neuroprotective and 
negative effects. The study by Christiansen demonstrates that NPY 
has a detrimental effect in ischaemic retina, a model induced by acutely 
raising intraocular pressure and restricting ocular perfusion. However, 
in diabetic retinas (and seen in the STZ model) more insidious patho-
physiological changes are observed, which show reduced NPY (gene 
and protein) expression in the mouse retina,30 more relevant to human 
diabetes, and emphasize the importance of the context and how the 
results are interpreted. In the current study, our approach was to inves-
tigate the adjunctive effect of extracellular NPY as a therapy to restore 
homeostasis, opposed to an association with a specific SNP in the NPY 
gene that may indicate causality in DR. The lack of genetic association 
reported in diabetic patients does not prevent therapeutic exploitation 
of the NPY pathway.
Taken together, these studies highlight the regulatory and ho-
meostatic role of the neurovascular unit that is disrupted in DR. The 
current data support that adjunctive NPY therapy sustains neuronal 
health and can attenuate at least in models the downstream effects 
of diabetic retinal vasculopathy, notably vascular leakage and neuro-
nal death, as well as the loss of Glia cells.
ACKNOWLEDG EMENTS
This work was supported by The Dunhill Medical Trust [grant num-
ber: R474/0216] and China Scholarships Council (CSC).
CONFLIC T OF INTERE S T
The authors declare that there is no conflict of interests regarding 
the publication of this paper.
AUTHORS'  CONTRIBUTIONS
Kepeng Ou, Dave A Copland, Lei Liu and Andrew D Dick designed 
this study. Kepeng Ou, Dave Copland and Youjian Li carried out 
experiments. Dave A Copland, Sofia Theodoropoulou and Jian Liu 
provided experimental methods. Kepeng Ou took on the statistical 
analysis. Kepeng Ou, David A Copland, Sofia Theodoropoulou, Sonja 
Mertsch, Stefan Schrader, Lei Liu and Andrew D Dick drafted the 
F I G U R E  5   NPY restores neurovascular function in diabetic retinas. Groups of diabetic mice received intravitreal injections (NPY; 
10 nmol) at 3 and 5 mo. A-C, Representative fundal and OCT images captured at 6 mo, showing no difference in retinal thickness between 
NPY-injected eyes and age-matched control eyes. The total retinal thickness is significantly reduced in the diabetic retina, primarily in IPL. D, 
ERG a-wave and b-wave responses represented by mean values of amplitudes in scotopic conditions. E, F, Representative confocal images of 
retinal whole mounts and quantification of Brn-3a immunostaining, showing that NPY prevents the loss of retinal ganglion cells in diabetic 
mice. G, H, Representative images and quantification of GFAP immunostaining, showing that NPY also protects against the loss of retinal 
astrocytes. I, J, Representative images 48 h following treatment demonstrate differences in the vasculature (leakage of Evans blue dye, 
which appears as red). Scale bar = 50 μm. The fluorescent intensity of Evans blue was quantified by ImageJ. *P < .05; **P < .01; ***P < .001; 
statistical analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons, and EGF was analysed using two-way 
ANOVA for multiple comparison
12  |     OU et al.
manuscript. David A Copland, Sofia Theodoropoulou, Lei Liu and 
Andrew D Dick provided critical suggestions and revised the manu-
script. All the authors had the approval of the submitted and pub-
lished versions.
DATA AVAIL ABILIT Y S TATEMENT
The data used to support findings of the study are available from the 
corresponding author upon request.
ORCID
Kepeng Ou  https://orcid.org/0000-0002-4145-7344 
R E FE R E N C E S
 1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 
2010;376:124-136.
 2. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic reti-
nopathy, diabetic macular edema and related vision loss. Eye Vis. 
2015;2:17.
 3. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. 
Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 
2002;47(Suppl. 2):S253-S262.
 4. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit 
in health and disease. Pharmacol Rev. 2005;57:173-185.
 5. Metea MR, Newman EA. Signalling within the neurovascular unit in 
the mammalian retina. Exp Physiol. 2007;92:635-640.
 6. Aung MH, Park H, Han MK, et al. Dopamine deficiency contributes 
to early visual dysfunction in a rodent model of type 1 diabetes. J 
Neurosci. 2014;34:726-736.
 7. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. 
Dendrite remodeling and other abnormalities in the retinal gan-
glion cells of Ins2 Akita diabetic mice. Investig Opthalmology Vis Sci. 
2008;49:2635.
 8. D’Cruz TS, Weibley BN, Kimball SR, Barber AJ. Post-translational 
processing of synaptophysin in the rat retina is disrupted by diabe-
tes. PLoS ONE. 2012;7:e44711.
 9. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascu-
lar and neural apoptosis to the pathology of diabetic retinopathy. 
Investig Opthalmol Vis Sci. 2011;52:1156.
 10. Lieth E, LaNoue KF, Antonetti DA, Ratz M. Diabetes reduces gluta-
mate oxidation and glutamine synthesis in the retina. Exp Eye Res. 
2000;70:723-730.
 11. Pannicke T, Iandiev I, Wurm A, et al. Diabetes alters osmotic swell-
ing characteristics and membrane conductance of glial cells in rat 
retina. Diabetes. 2006;55:633-639.
 12. Newman EA. Glial cell regulation of neuronal activity and blood 
flow in the retina by release of gliotransmitters. Philos Trans R Soc 
Lond B Biol Sci. 2015;370:20140195.
 13. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal 
occludin and glial fibrillary acidic protein in experimental diabetes. 
The Penn State Retina Research Group. Invest Ophthalmol Vis Sci. 
2000;41:3561-3568.
 14. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J 
Med. 2012;366:1227-1239.
 15. Gardner TW, Davila JR. The neurovascular unit and the patho-
physiologic basis of diabetic retinopathy. Graefe’s Arch Clin Exp 
Ophthalmol. 2017;255:1-6.
 16. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. 
Neuropeptide Y and neuropeptide Y receptor subtypes in brain and 
peripheral tissues. Prog Neurogibol. 1992;38:125-167.
 17. Michel MC. Receptors for neuropeptide Y: multiple sub-
types and multiple second messengers. Trends Pharmacol. Sci. 
1991;12:389-394.
 18. Jen PY, Li WWY, Yew DT. Immunohistochemical localization of neu-
ropeptide y and somatostatin in human fetal retina. Neuroscience. 
1994;60:727-735.
 19. Akiyama K, Nakanishi S, Nakamura NH, Naito T. Gene expression 
profiling of neuropeptides in mouse cerebellum, hippocampus, and 
retina. Nutrition. 2008;24:918-923.
 20. Bruun A, Tornqvist K, Ehinger B. Neuropeptide Y (NPY) immuno-
reactive neurons in the retina of different species. Histochemistry. 
1986;86:135-140.
 21. Blomqvist AG, Herzog H. Y-receptor subtypes–how many more? 
Trends Neurosci. 1997;20:294-298.
 22. Silva AP, Xapelli S, Grouzmann E, Cavadas C. The putative neuro-
protective role of neuropeptide Y in the central nervous system. 
Curr Drug Targets CNS Neurol Disord. 2005;4:331-347.
 23. Silva AP, Xapelli S, Pinheiro PS, et al. Up-regulation of neuropeptide 
Y levels and modulation of glutamate release through neuropeptide 
Y receptors in the hippocampus of kainate-induced epileptic rats. J 
Neurochem. 2005;93:163-170.
 24. Xapelli S, Bernardino L, Ferreira R, et al. Interaction between 
neuropeptide Y (NPY) and brain-derived neurotrophic factor in 
NPY-mediated neuroprotection against excitotoxicity: a role for mi-
croglia. Eur J Neurosci. 2008;27:2089-2102.
 25. Śmiałowska M, Domin H, Zięba B, et al. Neuroprotective effects 
of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. 
Neuropeptides. 2009;43:235-249.
 26. Santos-Carvalho A, Elvas F, Alvaro AR, Ambrósio AF, Cavadas C. 
Neuropeptide Y receptors activation protects rat retinal neural 
cells against necrotic and apoptotic cell death induced by gluta-
mate. Cell Death Dis. 2013;4:e636.
 27. Martins J, Elvas F, Brudzewsky D, et al. Activation of neuropeptide 
Y receptors modulates retinal ganglion cell physiology and exerts 
neuroprotective actions in vitro. ASN Neuro. 2015;7(4). https ://doi.
org/10.1177/17590 91415 598292
 28. Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z. 
Neuropeptide Y induces migration, proliferation, and tube forma-
tion of endothelial cells bimodally via Y1, Y2, and Y5 receptors. 
FASEB J. 2006;20:1924-1926.
 29. Christiansen AT, Sørensen NB, Haanes KA, et al. Neuropeptide Y 
treatment induces retinal vasoconstriction and causes functional 
and histological retinal damage in a porcine ischaemia model. Acta 
Ophthalmol. 2018;96:812-820.
 30. Campos EJ, Martins J, Brudzewsky D, et al. Impact of type 1 diabe-
tes mellitus and sitagliptin treatment on the neuropeptide Y system 
of rat retina. Clin Exp Ophthalmol. 2018;46:783-795.
 31. Ou K, Mertsch S, Theodoropoulou S, et al. Restoring retinal neuro-
vascular health via substance P. Exp Cell Res. 2019;380(2):115–123.
 32. Johnson TV, Martin KR. Development and characterization of an 
adult retinal explant organotypic tissue culture system as an in vitro 
intraocular stem cell transplantation model. Investig Opthalmol Vis 
Sci. 2008;49:3503.
 33. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced 
diabetes. Diabetologia. 2008;51:216-226.
 34. Cai J, Wu L, Qi X, et al. Placenta growth factor-1 exerts time-depen-
dent stabilization of adherens junctions following VEGF-induced 
vascular permeability. PLoS ONE. 2011;6:e18076.
 35. Chang M-L, Wu C-H, Jiang-Shieh Y-F, Shieh J-Y, Wen C-Y. Reactive 
changes of retinal astrocytes and Müller glial cells in kainate-in-
duced neuroexcitotoxicity. J Anat. 2007;210:54-65.
 36. Chen Y, Lu Q, Schneeberger EE, Goodenough DA. Restoration of 
tight junction structure and barrier function by down-regulation of 
the mitogen-activated protein kinase pathway in Ras-transformed 
Madin-Darby Canine kidney cells. Mol Biol Cell. 2000;11:849-862.
 37. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular 
complications in diabetes mellitus: distinct or continuum? Indian J 
Endocrinol Metab. 2016;20:546-551.
     |  13OU et al.
 38. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner 
TW. Neural apoptosis in the retina during experimental and 
human diabetes. Early onset and effect of insulin. J Clin Invest. 
1998;102:783-791.
 39. Rask-Madsen C, King GL. Vascular complications of diabetes: mech-
anisms of injury and protective factors. Cell Metab. 2013;17:20-33.
 40. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end 
products and diabetic complications. Korean J Physiol Pharmacol. 
2014;18:1-14.
 41. Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glyca-
tion end products and oxidative stress in type 2 diabetes mellitus. 
Biomolecules. 2015;5:194-222.
 42. Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of 
diabetic retinopathy: molecular mechanisms and therapeutic impli-
cations. Curr Med Chem. 2013;20:3241-3250.
 43. Qian H, Ripps H. Neurovascular interaction and the pathophysiol-
ogy of diabetic retinopathy. J. Diabetes Res. 2011;2011:1–11.
 44. Feit-Leichman RA, Kinouchi R, Takeda M, et al. Vascular damage in a 
mouse model of diabetic retinopathy: relation to neuronal and glial 
changes. Investig Opthalmol Vis Sci. 2005;46:4281.
 45. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett 
ME. Vascular endothelial growth factor in eye disease. Prog Retin 
Eye Res. 2008;27:331-371.
 46. Anderson JM, Balda MS, Fanning AS. The structure and regulation 
of tight junctions. Curr Opin Cell Biol. 1993;5:772-778.
 47. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. 
Vascular endothelial growth factor induces rapid phosphorylation 
of tight junction proteins occludin and zonula occluden 1. A poten-
tial mechanism for vascular permeability in diabetic retinopathy and 
tumors. J Biol Chem. 1999;274:23463-23467.
 48. Wallez Y, Huber P. Endothelial adherens and tight junctions in vas-
cular homeostasis, inflammation and angiogenesis. Biochim Biophys 
Acta Biomembr. 2008;1778:794-809.
 49. Takano K, Kojima T, Sawada N, Himi T. Role of tight junctions in 
signal transduction: an update. EXCLI J. 2014;13:1145-1162.
 50. Aveleira CA, Lin C-M, Abcouwer SF, Ambrósio AF, Antonetti DA. 
TNF-α signals through PKCζ/NF-κB to alter the tight junction com-
plex and increase retinal endothelial cell permeability. Diabetes. 
2010;59:2872-2882.
 51. Ferreira R, Xapelli S, Santos T, et al. Neuropeptide Y modulation 
of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in 
microglia. J Biol Chem. 2010;285:41921-41934.
 52. Cromer WE, Zawieja SD, Tharakan B, Childs EW, Newell MK, 
Zawieja DC. The effects of inflammatory cytokines on lymphatic 
endothelial barrier function. Angiogenesis. 2014;17:395-406.
 53. Ko J-A, Yanai R, Nishida T. Up-regulation of ZO-1 expression and 
barrier function in cultured human corneal epithelial cells by sub-
stance P. FEBS Lett. 2009;583:2148-2153.
 54. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired gluta-
mate metabolism in short-term experimental diabetic retinopathy. 
Penn State Retina Research Group. Diabetes. 1998;47:815-820.
 55. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, 
Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion 
cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 
1996;37:1618-1624.
 56. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate tox-
icity in retinal ganglion cells. Vis Res. 1997;37:3483-3493.
 57. Deng J, Wu DZ, Gao R. Detection of glutamate and gamma-amino-
butyric acid in vitreous of patients with proliferative diabetic reti-
nopathy. Yan Ke Xue Bao = Eye Sci. 2000;16:199-202.
 58. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal gluta-
mate in diabetes and effect of antioxidants. Neurochem Int. 
2001;38:385-390.
 59. Álvaro AR, Martins J, Costa A, et al. Neuropeptide Y protects reti-
nal neural cells against cell death induced by ecstasy. Neuroscience. 
2008;152:97-105.
 60. Bull ND, Johnson TV, Welsapar G, DeKorver NW, Tomarev SI, 
Martin KR. Use of an adult rat retinal explant model for screening 
of potential retinal ganglion cell neuroprotective therapies. Investig 
Opthalmol Vis Sci. 2011;52:3309.
 61. Murali A, Ramlogan-Steel CA, Andrzejewski S, Steel JC, Layton CJ. 
Retinal explant culture: a platform to investigate human neuro-ret-
ina. Clin Exp Ophthalmol. 2019;47:274-285.
 62. Álvaro AR, Rosmaninho-Salgado J, Ambrósio AF, Cavadas C. 
Neuropeptide Y inhibits [Ca2+]i changes in rat retinal neurons through 
NPY Y1, Y4, and Y5 receptors. J Neurochem. 2009;109:1508-1515.
 63. Decressac M, Pain S, Chabeauti P-Y, et al. Neuroprotection by 
neuropeptide Y in cell and animal models of Parkinson’s disease. 
Neurobiol Aging. 2012;33:2125-2137.
 64. Derkac I, Januleviciene I, Sepetiene R, Valiauga R, Velickiene D. The 
association of cep135 rs4865047 and NPY2R rs1902491 single nu-
cleotide polymorphisms (SNPS) with rapid progression of prolifer-
ative diabetic retinopathy in patients with type 1 diabetes mellitus. 
Med Sci Monit. 2018;24:8891-8898.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.  
How to cite this article: Ou K, Copland DA, Theodoropoulou 
S, et al. Treatment of diabetic retinopathy through 
neuropeptide Y-mediated enhancement of neurovascular 
microenvironment. J Cell Mol Med. 2020;00:1–13. https ://doi.
org/10.1111/jcmm.15016 
